
HNGE Stock Forecast & Price Target
HNGE Analyst Ratings
Bulls say
Hinge Health is supported by accelerating demand, with 3Q26 downloads up 59% y/y, September downloads up 100% y/y, and retention metrics still strong as active-user engagement improved even with only modest MAU softness. Its fundamentals also appear durable because management cited win-rates above 80%, 97% retention, $960-970 million of 2026 calculated billings, and strong pipeline visibility from enterprise and SMB selling season, while SensorTower data shows it extending a major lead over Sword. Looking ahead, the business has multiple growth levers in higher-yield cohorts, Hinge Select, surgery, and migraine, and the outlook implies 2027 organic revenue growth of 33% with meaningful margin expansion from a scalable, high-visibility platform.
Bears say
Hinge Health is exposed to significant execution risk because its growth depends on attracting new clients, retaining existing ones on favorable terms, and meeting performance guarantees, any of which could materially hurt revenue, operations, and financial condition. Its reliance on a limited number of health plans and other partners, combined with meaningful upfront relationship costs, raises the risk that weak renewals or slow expansion will prevent recovery of invested capital. The company also faces competitive and product risk if it cannot continuously enhance its AI-powered MSK platform, maintain market acceptance, and deliver high-quality implementation and support in a shifting healthcare and regulatory landscape.
This aggregate rating is based on analysts' research of Hinge Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HNGE Analyst Forecast & Price Prediction
Start investing in HNGE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Hinge Health Inc (HNGE) Forecast
HNGE Analyst Forecast & Price Prediction
Start investing in HNGE
Order type
Buy in
Order amount
Est. shares
0 shares